

December 21, 2022

BSE Ltd. Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001

BSE Scrip Code: 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref.: Our letter dated December 14, 2022

We refer to our above referred letter intimating you about the approval by the Board of directors of the Company for acquisition of 'Razel' franchise from Glenmark Pharmaceuticals Limited. In compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we further wish to inform you that the aforesaid transaction of acquisition from Glenmark Pharmaceuticals Limited has been successfully completed today.

You are requested to take the same on record.

Thanking you,

Yours sincerely For J. B. Chemicals & Pharmaceuticals Ltd.

Sandeep Phadnis Vice President – Secretarial & Company Secretary

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited, CIN: L24390MH1976PLC019380 Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road, Worli, Mumbai – 400030, T:+91 22 24822222 Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited, CIN: L24390MH1976PLC019380 Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

www.jbpharma.com